Investment Rating - The report assigns a "Buy" rating with a target price of $31.1, indicating a potential upside of 41% from the current price of $22.16 [2][5][6]. Core Insights - The company achieved a revenue growth of 59% year-over-year, with Q4 revenue reaching $620 million, although gross margin decreased by 4.9 percentage points to 71.9% [3]. - The company is expanding its subscription base, with a 13% increase in subscribers to 2.51 million, and a 31% increase in personalized subscription users [4]. - The company is actively acquiring new businesses, including the purchase of Eucalyptus for $1.15 billion, which is expected to contribute significantly to future revenue [4]. - The company has settled a lawsuit with Novo Nordisk and is transitioning to sell the original brand of GLP-1 drugs, which is projected to have a market size of $100-150 billion by 2030 [5]. Financial Summary - For the fiscal year ending December 31, 2025, the company reported revenues of $2.35 billion, with a net profit of $128 million and an adjusted EBITDA of $318 million, reflecting an EBITDA margin of 13.5% [7]. - The company forecasts revenues of $2.79 billion for 2026, with a projected net profit of $56 million and an adjusted EBITDA of $259 million [7]. - The company’s international revenue reached $140 million in 2025, with expectations to exceed $1 billion in three years [4].